2015 American Transplant Congress
Incidence, Determinants and Outcome of Kidney Transplantation for End Stage Renal Disease After Heart Transplantation
Objectives: Progressive renal failure is a frequent complication following heart transplantation (HTx), is generally attributed to calcineurin inhibitor (CNI) based immunosuppression, and may result in…2015 American Transplant Congress
New Insights in Clinical and Genetic Determinants of Longitudinal Dose-Corrected CNI Exposure in Children After Renal Transplantation
Purpose: Calcineurin-inhibitors (CNI) have a narrow therapeutic index and dosing is difficult due to inter- and intra-individual variation in pharmacokinetics (PK). Polymorphisms in genes involved…2015 American Transplant Congress
Spironolactone Prevents Calcineurin Inhibitors Toxicity in Renal Allografts. Preliminary Report
Nephrology, Hospital General "Dr Miguel Silva", Morelia, Michoacan, Mexico.
Introduction: Calcineurin inhibitors (CI) introduction was a transcendental event in the transplant medicine history. Actually, CI are considered the cornerstone in the immunosuppression treatment because…2015 American Transplant Congress
Incidence and Risk Factors of Contrast-Induced Nephropathy in Renal Allograft Recipients
University of Cincinnati, Cincinnati.
Background: Contrast-induced nephropathy (CIN) is associated with a significant increase in mortality and morbidity in patients with native kidneys. Data regarding CIN in renal allografts…2015 American Transplant Congress
Variants Associated With Tacrolimus Troughs in European American Kidney Transplant Recipients: A Genome Wide Association Study
Tacrolimus (tac) is dependent on CYP3A4/5 for metabolism. Variability in the metabolism is influenced by CYP3A5*3 alleles. This variant and clinical factors explain around 50%…2015 American Transplant Congress
Clinical Outcomes of Kidney Transplan Recipients After Sirolimus Or Everolimus Conversion. Experience in a Single Center
Transplant Unit, Fundación Valle del Lili, Cali, Colombia.
Introduction. The use of m_TOR inhibitors sirolimus (SRL) and everolimus (EVL), in kidney transplant recipients (KTR) is an alternative immunosuppressive therapy to reduce or withdrawal…2015 American Transplant Congress
Safety and Efficacy of Conversion from Conventional Twice Daily Tacrolimus to Once Daily Extended Release Tacrolimus in Stable Pancreas Transplant (SPK and PAK) Recipients
Surgery, Multi-Organ Transplant, Toronto General Hospital, Toronto, ON, Canada.
Background: A once-daily, modified-release oral formulation of tacrolimus has been developed to simplify dosing and improve medication adherence. There is limited data on the implementation…2015 American Transplant Congress
Frequencies of CD4+25hiFoxp3+ T Cells in Long-Term Follow-Up of Sirolimus-Converted Kidney Transplant Recipients
Background: Tacrolimus(TAC) and Sirolimus(SRL) are commonly used immunosuppressive drugs in kidney transplantation. SRL has been shown to induce the expansion of regulatory T cells in…2015 American Transplant Congress
NK Cells of Kidney Transplant Recipients Show a Reduced Capacity to Produce Cytokines But Retain Their Cytotoxic Capacity
The role of NK cells in either graft rejection or tolerance induction is still discussed controversially. In order to clarify the effect of long-term immunosuppression…2015 American Transplant Congress
"What's the Mileage?" Determining the Length of Time in Which Renal Function Returns to Pre-Calcineurin Discontinuation Levels in Patients With Interstitial Fibrosis
The Ohio State University, Columbus.
Calcineurin Inhibitors (CNI) use may be associated with progressive renal dysfunction. Clinical trials have shown that CNI minimization or discontinuation may aid in improvement in…
American Transplant Congress abstracts